PARIS, France, July 27, 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet.
Dr Gilbert Wagener brings to Pharnext 30 years of experience in medical affairs and R&D in various therapeutic areas, including neurological and/or rare diseases, and on products at various. | June 15, 2023
PHARNEXT: Pharnext appoints Gilbert Wagener, M.D., Ph.D. as Chief Medical Officer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
PARIS, France, June 14th, 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high. | June 14, 2023
PHARNEXT: The Latest Findings From CMTMe, a 'Real-World' Digital Lifestyle Study on Charcot-Marie-Tooth Diseases ('CMTs'), to be Presented at the 2023 Peripheral Nerve Society ('PNS') Annual Meeting finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.